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Background/aim: The majority of psoriatic arthritis (PsA) patients present at dermatology clinics with cutaneous psoriasis up to
10 years prior to arthritis onset; therefore, applying a suitable screening tool to detect PsA early is essential for dermatologists. This
study aimed to validate and evaluate the Persian version of two PsA screening questionnaires, the early arthritis for psoriatic patients
questionnaire (EARP) and the psoriasis epidemiology screening tool (PEST) in Iranian psoriatic patients.
Materials and methods: In this cross-sectional study, psoriatic patients who presented to the dermatology clinic without a previously
established PsA were asked to fill out the Persian version of EARP and PEST. PsA was diagnosed by a rheumatologist based on the
fulfillment of the classification criteria for psoriatic arthritis. Receiver operator characteristic (ROC) curves, sensitivity, and specificity
were calculated for both questionnaires.
Results: A total of 75 patients (33 [44%] female, 42 [56%] male, with a mean age of 43.2 ± 14.6) were enrolled in the study. The prevalence
of PsA based on rheumatologist diagnosis was 25.3% (19 patients had PsA). The ROC curve analysis of EARP and PEST were 0.949 (95%
CI: 0.897–1) and 0.922 (95% CI: 0.834–1). The sensitivity of EARP and PEST questionnaires was 94.7% and 58%, respectively, while the
specificity was 78.6% and 96.4%, respectively, with a cut-off of 3.
Conclusion: The Persian version of both questionnaires showed good performance. We suggest EARP as a screening tool for PsA in the
dermatology clinics due to much higher sensitivity with acceptable specificity compared to PEST.
Key words: Arthritis, psoriatic, screening, psoriasis epidemiology screening tool, early arthritis for psoriatic patients questionnaire

1. Introduction
Psoriatic arthritis (PsA) is an inflammatory skeletal disease
associated with cutaneous psoriasis. Approximately
20%–30% of psoriasis patients will develop PsA during
their disease course [1]. Delayed PsA diagnosis has been
shown to be associated with impaired physical function,
more peripheral joint erosions, and more severe axial
joints involvement [2]. Therefore, early PsA detection is
important to prevent irreversible joint damage.
Of note, the majority of PsA patients present at
dermatology clinics with cutaneous psoriasis up to 10
years prior to arthritis onset [3]. Therefore, dermatologists
play a key role in the early detection of PsA. Although
various screening tools have been developed to help early
PsA detection and referral to rheumatologists, a highly
sensitive screening tool with acceptable specificity is vital
for dermatologists.

To classify PsA in the early stages, the group for
research and assessment of psoriasis and psoriatic arthritis
has developed the classification criteria for PsA (CASPAR)
[4]. The currently used screening tools in psoriatic patients
are psoriatic arthritis screening and evaluation (PASE)
(15 questions), the psoriasis epidemiology screening tool
(PEST) (5 questions), and the early arthritis for psoriatic
patients questionnaire (EARP) (10 items) [5–7]. Based on
different studies, PASE, PEST, and EARP have been shown
to have a wide range of sensitivities and specificities, 24%–
90% and 40%–94%, respectively. This wide range might
be explained by various skeletal involvements in different
studies or ethnic variabilities [8].
The pattern of musculoskeletal involvement in PsA
varies among ethnic groups [3]. For example, spinal
involvement has been reported more frequently in Asian
patients [9].
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The present study was conducted in consideration of
the ethnic variability, the necessity of choosing a sensitive
and specific screening tool in dermatology clinics, and the
lack of a verified screening tool in the Persian language.
The study aimed to validate the Persian version of PEST
and EARP and to evaluate the sensitivity and specificity
of PEST and EARP questionnaires in diagnosing PsA in
Iranian patients with psoriasis (Pso) with CASPAR as the
gold standard.
2. Materials and methods
The present cross-sectional study was held at the psoriasis
clinic at Razi dermatology hospital, Tehran University of
medical sciences, between March 2019 and March 2020.
The inclusion criteria were cutaneous psoriasis patients
older than 18 years for whom PsA had not been diagnosed
before. Informed consent was obtained from all patients.
The study was approved by the Tehran University of
Medical Sciences ethics committee.
EARP [7] and PEST [6] were translated from English
into the Persian language based on Beaton et al. steps [10].
First, the questionnaires were translated from English to
Persian by two independent bilingual Persian speaking
translators. Second, the discrepancies were resolved by a
consensus between two dermatologists and the translators.
Third, a back-translation was performed from Persian
to English by two other bilingual translators. The backtranslation versions were compared to the original English
language version by a committee consisting of three
dermatologists and the four translators. The discrepancies
were resolved and prefinal Persian versions were
developed. Twenty patients, 18 years or older, were asked
to answer the prefinal Persian versions. The patients were
asked to explain their problems in answering the prefinal
versions. The Persian versions of EARP and PEST were
finalized after resolving patients’ pretesting problems.
Psoriatic patients without any history of PsA referred
to psoriatic clinics were enrolled in the study. Clinical
demographic data were recorded including age, sex,
disease duration, PASI score, and nail involvement. The
diagnosis of PsA was made by a rheumatologist based on
the CASPAR criteria.
2.1. Statistical analysis
An independent two-sample t-test was used to compare
two quantitative variables. The association between two
qualitative samples was evaluated by the chi-square test,
and if needed, nonparametric tests, including the Mann–
Whitney test and the Fisher exact test, were used. Two
approaches were used for evaluating the performance of
EARP and PEST questionnaires in detecting arthritis in
psoriatic patients. First, multivariate logistic regression
was applied. In this approach, the questions of each
questionnaire (EAPR AND PEST) were considered
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as predictors of having arthritis compared to the
rheumatologist diagnosis of arthritis as the gold standard.
The performance of logistic regression in predicting
patients’ arthritis status was determined by using the
AUC (area under the curve) index obtained from the
receiver operator characteristic (ROC) curve and its
corresponding cutoff value calculated based on Youden
index for each questionnaire. In the second approach, the
sum of each questionnaire score was measured and the
AUC index was calculated by considering this score as
a continuous variable and patients’ arthritis status based
on rheumatologist diagnosis as the gold standard in ROC
analysis; then the value of 3 was considered as a standard
cut off value. In both approaches, we reported sensitivity
and specificity. All statistical analysis was performed in
SPSS software (version 25, IBM Corp., Armonk, NY,
USA). In this study, we considered 0.05 as a statistically
significant level. The Kappa coefficient was used to evaluate
the agreement between the gold standard rheumatologist
diagnosis and questionnaires’ scores.
3. Results
A total of 75 patients (33 [44%] female, 42 [56%] male,
with a mean age of 43.2 ± 14.6) were enrolled in the study.
The prevalence of PsA based on rheumatologist diagnosis
was 25.3% (19 patients). The demographic data of patients
with and without arthritis are shown in Table 1.
The internal consistency of items from the Persian
version of EARP and PEST was good (Cronbach’s alpha
coefficients were 0.794 [95% CI: 0.73–0.86] and 0.645
[95% CI: 0.53–0.76], respectively).
The sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPPV) were
calculated for each question of the two questionnaires
(Table 2). Considering EARP, the question with the highest
sensitivity (100%) and NPPV (100%) was question 1 (Q1),
asking about joint hurting, the question with maximum
specificity (100%) and PPV (100%) was Q7, asking on the
swelling or hurting of fingers for more than 3 days. For
the PEST analysis, the question with maximum sensitivity
(73.6) was Q1, asking on ever having a completely swollen
joint; the question with maximum specificity (100%) and
PPV (100%) was Q5, asking about having a swollen finger
or toe for no apparent reason and the questions with
maximum NPPV were Q1 and Q5, both with NPPV of
87.5%.
In univariate analysis, all the questions of EARP
were significantly associated with PsA, except questions
8 and 10 (Table 3). In multivariate analysis of EARP, the
most relevant questions to arthritis were question 6 and
question 4; the adjusted odds ratios were 27.35 (CI: 2.27–
329.8) and 11.8 (CI: 2.02–68.9), respectively. Regarding
the PEST questionnaire, all questions were significantly
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Table 1. Demographic characteristics of psoriasis patients with and without arthritis. N/A: not
applicable; PsA: psoriatic arthritis; SD standard deviation.
PsA (19)

No PsA (56)

P-value

Sex (Female/Male)

14/5

19/37

0.003

Age, years (SD)

46.79 (12.97)

41.98 (16.23)

0.246

Duration of psoriasis

12.47 (11.82)

13.05 (11.3)

0.728

Age of disease onset

34.2 (17.5)

29.63 (17.1)

0.324

PASI score (SD)

5.72 (6.1)

3.2 (3.8)

0.179

Smoking pack year (SD)

1.00 (3.45)

2.5 (5.51)

0.395

Psoriatic nail

Yes
No

8 (42.1%)
11 (57.9%)

16 (28.5%)
40 (71.4%)

0.274

Scalp psoriasis

Yes
No

10 (52.6%)
9 (47.3%)

17 (30.3%)
39 (69.7%)

0.08

Flexural psoriasis (%)

Yes
No

8 (42.1%)
11 (57.9%)

27 (48.2%)
29 (51.8%)

0.64

Family history

Yes
No

14 (73.7%)
5 (26.3%)

32 (57.1%)
24 (42.8%)

0.201

Axial involvement

Yes
No

7 (36.8%)
12 (63.2%)

N/A
N/A

N/A

6 (31.6%)
13 (68.4%)

N/A
N/A

N/A

Polyarticular
Oligoarticular

associated with PsA in univariate analysis (Table 4), and
the most relevant questions to PsA were questions 1 and
2; the adjusted odds ratios were 61 (CI: 4.64–802.6) and
31.38 (CI: 3.74–263.47), respectively.
The AUC (area under the curve) calculated based
on multivariate analyses and the Youden index of EARP
and PEST was 0.949 (95% CI: 0.89–1.00) and 0.922 (95%
CI: 0.834–1.00), respectively (Figure). The calculated
sensitivity and specificity based on this method are shown
in Table 5. When the cutoff of 3 was selected for EARP
and PEST based on the previous studies [7], the calculated
sensitivity and specificity by ROC curve are shown in
Table 5. As shown in Table 5, the sensitivity of 0.947 that
was measured for EARP was higher than that of PEST at
0.58. Conversely, the specificity of EARP was lower than
that of PEST (0.786 compared to 0.964).
4. Discussion
This study showed that the Persian version of EARP and
PEST had an acceptable performance for screening PsA in
Iranian psoriatic patients presenting to the dermatology
clinic (EARP, sensitivity = 0.947 and specificity = 0.786;
PEST, sensitivity = 0.58 and specificity = 0.964). The
sensitivity of EARP in this study was higher than the
primary validation study and other language versions
validation studies, while the measured specificity was

slightly lower than the previous studies [5,7]. The sensitivity
of PEST in this study (58%) was much lower than in the
primary validation study (92%) and other language version
study (79.3%), while the measured specificity was much
higher than the primary validation study (78%) and other
language version study (79.3%) [5,6]. Similar to this study,
Mishra et al. also reported very low sensitivity (53.3%)
for the PEST questionnaire and they considered the low
sensitivity as a major drawback for this questionnaire [11].
The different performances between various studies
may result from different patient characteristics, including
the prevalence of PsA among psoriatic patients, the pattern
of articular involvement (axial versus peripheral), and
ethnic variabilities. The prevalence of PsA in this study
was 25.3%, whereas a range of 12.9% to 78.6% of PsA was
reported in various studies evaluating the PsA screening
tools [5–7]. In this study, patients without a previous
diagnosis of PsA were included, whereas other studies
enrolled patients with both established diagnosis of PsA
and newly diagnosed ones.
The difference in the pattern of articular involvement
may also explain the variation in screening tool
performances. The majority of current PsA screening tools
evaluate peripheral arthritis more than axial arthritis;
for example, some studies showed that PEST missed
a high proportion of axial involvement and enthesitis
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Table 2. The sensitivity, specificity, positive predictive value (PPV), and negative predictive values (NPPV) calculated for questions in
the EARP and PEST questionnaires. PsA: psoriatic arthritis.
PsA
(Y/N)

No PsA
(Y/N)

Sensitivity% Specificity% PPV% NPPV%

19/0

17/39

100

69.6

52.7

100

2. Have you taken anti-inflammatory more than twice a week for
8/11
joint pain in the last 3 months?

6/50

42.1

89.2

57.1

81.9

3. Do you wake up at night because of low back pain?

7/12

5/51

36.8

91

58.3

80.9

4. Do you feel stiffness in your hands for more than 30 min in
the morning?

10/9

5/51

52.6

91

66.6

85

5. Do your wrists and fingers hurt?

12/7

9/47

63.1

83.9

57.1

87

6. Do your wrists and fingers swell?

8/11

2/54

42.1

96.4

30

83

7. Does one finger hurt and swell for more than 3 days?

4/15

0/56

19

100

100

78.8

8. Does your Achilles tendon swell?

1/18

2/54

5

96

66

75

9. Do your feet or ankles hurt?

13/6

12/44

68.4

78.5

52

88

10.Do your elbow or hips hurt?

3/16

3/53

15.7

94

50

76.8

1. Have you ever had a swollen joint (or joints)?

14/5

2/54

73.6

96.4

91.5

87.5

2. Has a doctor ever told you that you have arthritis?

10/9

2/54

52.6

96.4

83.3

85.7

3. Do your fingernails or toenails have holes or pits?

7/12

5/51

36.8

91

80.9

50

4. Have you had pain in your heel?

5/14

2/54

55.5

96.4

79.4

71.4

5. Have you had a finger or toe that was completely swollen and
painful for no apparent reason?

11/8

0/56

57.8

100

100

87.5

Questionnaire
EARP
1. Do your joints hurt?

PEST

[12]. In this study, vertebral and iliac involvement was
much lower than in Chiowchanwisawakit et al.’s study
(36.8% compared to 56%, respectively), which may be
responsible for the different performances of PEST in the
two studies [5]. However, in this study, the performance
of the questionnaires was not assessed in subgroups of
patients with different patterns of articular involvement
(including axial, polyarticular, and oligoarticular)
due to the low number of patients in each subgroup.
This limitation could have affected the sensitivity and
specificity measured in this study.
The question most associated with arthritis in the
EARP questionnaire in this study was question 6, “Do
your wrists and fingers swell?”, in concordance with
Chiowchanwisawakit et al.’s study that found the same
question to be the most relevant question to arthritis
[5]. The most relevant question to arthritis in the PEST
questionnaire was question 1, “Have you ever had a
swollen joint (or joints)?” and the second most relevant
question was question 2, “Has a doctor ever told you that
you have arthritis?” in this study, similar to Ibrahim et
al.’s study that reported these two questions as the most
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significant predictors of arthritis in psoriatic patients
[6]. Therefore, these questions can be most helpful for
deciding whether to refer patients to rheumatologists.
Selecting an optimized screening tool depends on
the patients’ characteristics; in this study, the sensitivity
of PEST (58%) was lower than that of EARP (94.7%).
Considering the prevalence of nearly 20%–30% of PsA
in psoriatic patients presenting to the dermatology
clinic, a screening test with high sensitivity and medium
specificity seems ideal to ensure no cases of true PsA are
missed and also not over referring psoriatic patients to
rheumatology clinics as well. Therefore, in the Iranian
population of psoriatic patients, EARP is suggested
more often for screening PsA due to its higher sensitivity
compared to PEST. However, in a population of general
patients in whom the prevalence of PsA is much lower
than psoriatic patients, the PEST questionnaire may be
an ideal option with fewer questions and more simplicity
of application.
The strength of this study was enrolling psoriatic
patients without a previous history of PsA. Previous
studies that included both diagnosed and undiagnosed
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Table 3. Univariate and multivariate analysis of the Persian version of EARP. Unadjusted odds ratio ‡Fisher exact test. *Adjusted odds
ratio for Q2, Q3, Q4, Q5, Q6, Q8, Q9, Q10. **Multivariate logistic regression, Hosmer and lemeshow test (Chi-square = 3.355, df = 4,
P-value = 0.5), Nagelkerke’s R square = 0.614.
Arthritis

N(%)

UAOR†
(95% CI UAOR)

P-value‡

AOR* (95% CI AOR)

P-value**

Q1

Negative
Positive

Yes
No
Yes
No

17 (30.4%)
39 (69.6%)
19 (100%)
0 (0.0%)

-

<0.001

-

-

Q2

Negative
Positive

Yes
No
Yes
No

6 (10.7%)
50 (89.3%)
8 (42.1%)
11 (57.9%)

6.06 (1.75, 21.02)

0.005

0.631 (0.08-4.8)

0.658

Q3

Negative
Positive

Yes
No
Yes
No

5 (8.9%)
51 (91.1%)
7 (36.8%)
12 (63.2%)

5.95 (1.61-22.02)

0.009

1.87 (0.21-16.8)

0.577

Q4

Negative
Positive

Yes
No
Yes
No

5 (8.9%)
51 (91.1%)
10 (52.6%)
9 (47.4%)

<0.001

11.8 (2.02-68.9)

0.006

Q5

Negative
Positive

Yes
No
Yes
No

9 (16.1%)
47 (83.9%)
12 (63.2%)
7 (36.8%)

<0.001

2.75 (0.51-14.76)

0.239

Q6

Negative
Positive

Yes
No
Yes
No

2 (3.6%)
54 (96.4%)
8 (42.1%)
11 (57.9%)

<0.001

27.35 (2.27-329.8)

0.009

Q7

Negative
Positive

Yes
No
Yes
No

0 (0.0%)
56 (100%)
4 (21.1%)
15 (78.9%)

-

0.003

-

-

Q8

Negative
Positive

Yes
No
Yes
No

2 (3.6%)
54 (96.4%)
1 (5.3%)
18 (94.7%)

1.5 (0.13-17.54)

0.745

0.41 (0.01-21.1)

0.655

Q9

Negative
Positive

Yes
No
Yes
No

12 (21.4%)
44 (78.6%)
13 (68.4%)
6 (31.6%)

7.94 (2.49-25.32)

<0.001

5.1 (0.82-31.5)

0.08

Q10

Negative
Positive

Yes
No
Yes
No

3 (5.4%)
53 (94.6%)
3 (15.8%)
16 (84.2%)

3.31 (0.61-18.05)

0.166

1.81 (0.12-28.3)

0.672

Variables

11.33 (3.13-41.02)

8.95 (2.77-28.95)

19.64 (3.66-105.32)
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Table 4. Univariate and multivariate analysis of the Persian version of PEST. † Unadjusted odds ratio. ‡Fisher exact test. *adjusted Odds
ratio for Q1, Q2, Q3, Q4. **Multivariate logistic regression. Hosmer and lemeshow test (chi-square = 2.834, df = 2, P-value = 0.244).
Nagelkerke’s R square = 0.679.
Variable

Arthritis

N(%)

UAOR†

95% CI UAOR

P-value‡

AOR*

95% CI AOR

P-value

Q1

Negative
Positive

Yes
No
Yes
No

1 (1.8%)
55 (98.2%)
10 (52.6%)
9 (47.4%)

61.11

6.96, 536.88

<0.001

Ref
61

Ref
4.64, 802.66

0.002

Q2

Negative
Positive

Yes
No
Yes
No

2 (3.6%)
54 (96.4%)
10 (52.6%)
9 (47.4%)

30

5.62, 160.03

<0.001

Ref
31.38

Ref
3.74, 263.47

0.001

Q3

Negative
Positive

Yes
No
Yes
No

5 (8.9%)
51 (91.1%)
6 (31.6%)
13 (68.4%)

4.71

1.24, 17,87

0.025

Ref
1.57

Ref
0.18, 14

0.684

Q4

Negative
Positive

Yes
No
Yes
No

1 (1.8%)
55 (98.2%)
4 (21.1%)
15 (78.9%)

14.67

1.52, 141.18

0.013

Ref
20.04

Ref
1.1, 364.34

0.043

Q5

Negative
Positive

Yes
No
Yes
No

21 (37.5%)
35 (62.5%)
19 (100%)
0 (0.0%)

-

-

<0.001

-

-

-

Figure. The AUC (area under the curve) calculated based on multivariate analyses and
Youden index for EARP and PEST.
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Table 5. Calculated sensitivity and specificity for EARP and PEST questionnaires with a cut off of 3 and without a
predefined cut-off based on the Youden index by ROC curve analysis. AUC: area under the curve
AUC (95% CI)

Sensitivity

Specificity

Cut-off value

EARP

0.923 (0.882-0.99)

0.947

0.786

3

PEST

0.936 ( 0.864-0.983)

0.58

0.964

3

EARP

0.949 (0.897-1.00)

94.7%

85.7

0.213

PEST

0.922 (0.834 – 1.00)

78.9

94.6

0.574

Based on Youden-index

PsA might have overestimated the sensitivity due to recall
bias in patients with established PsA [5,6].
In summary, both EARP and PEST questionnaires
showed acceptable performances in the Iranian psoriatic
population without a previously established diagnosis of
psoriatic arthritis (sensitivity 94.7% and 58%, specificity
78.6% and 96.4%, respectively). The most relevant
questions in both questionnaires were questions asking
about the swelling of joints. Due to the higher sensitivity
calculated for EARP compared to PEST in this study, we
suggest applying EARP for screening psoriatic arthritis

in psoriatic patients with a higher prevalence of arthritis
compared to the general population.
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